Becton, Dickinson and Company – Consensus Says Potential Rise of 14.1%
Becton, Dickinson and company found using the ticker (BDX) now have 15 analysts covering the stock with the consensus suggesting a rating of “Buy”. The target price is between 300 and 260 and has an average target of 279.2. Given that the previous close of shares was at 244.79, this would indicate that there is a potential upside of 14.1%. The 50 day moving average is now at 249.05 and the 200 day MA is 247.19. The company’s market capitalization is $ 71,099 million. Visit the company’s website at: http://www.bd.com
Becton, Dickinson and Company develops, manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products around the world. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, core lines, acute dialysis catheters, vascular care and preparation products, IV connectors and needleless extensions, closed system drug transfer, detection of hazardous drugs, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication preparation workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles and other preparations for the treatment of diabetes; and pre-fillable drug delivery systems. Its BD Life Sciences segment provides sample and blood collection products and systems; automated blood and tuberculosis culture, molecular testing, microorganism identification and drug sensitivity, and liquid based cytology systems, as well as rapid diagnostic tests, automation products microbiology laboratory and plated media products; and fluorescence activated cell sorters and analyzers, antibodies and kits, reagent systems and solutions for high throughput single-cell gene expression analysis, as well as diagnostic / monitoring reagents and analyzers in clinical, immunological and transplantation oncology. The Company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery and other surgical products; prevention of surgical infections, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and intensive care products. Becton, Dickinson and Company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.